Home » Pipeline
Pipeline
May 10, 2021
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| COVID-19 Trials and Actions | |||
| HDT Bio Gennova Biopharmaceuticals |
RNA-based COVID-19 vaccine | COVID-19 | first patient dosed in phase 1/2 trial in India |
| Adagio Therapeutics | ADG20 vaccine | COVID-19 | phase 2/3 trial initiated |
| Novavax | NVX-CoV2373 vaccine | COVID-10 in patients age 12 to 17 | pediatric expansion of phase 3 clinical trial initiated |
| Other Trials and Actions | |||
| Genascence | GNSC-001 | osteoarthritis | dosing of all patients in phase 1 trial complete |
| Neoleukin Therapeutics | NL-201 | advanced solid tumors | phase 1 trial initiated |
| NervGen Pharma | NVG-291 | nerve damage | first patient dosed in phase 1 trial |
| Vivace Therapeutics | VT3989 | refractory metastatic solid tumors | first patient dosed in phase 1 trial in the U.S. and Australia |
| Repare Therapeutics | RP-6306 | PKMYT1 inhibitor-sensitive cancers | first patient dosed in phase 1 trial |
| Landos Biopharma | NX-13 | ulcerative colitis | first patient dosed in phase 1b trial |
| Vaxart | oral tablet norovirus vaccine | norovirus | first patient enrolled in phase 1b boosting regimen trial |
| Cerecor | CERC-007 | adult-onset Still’s disease | first patient dosed in phase 1b trial |
| Treadwell Therapeutics | CFI-400945 | PLK4 inhibitor in patients with leukemia | first patient dosed in phase 1b/2 trial |
| Merus | MCLA-129 | advanced lung cancer and other solid tumors | first patient treated in phase 1/2 clinical trial |
| Peptomyc | OMO-103 lead compound | advanced solid tumors | first patient dosed in phase 1/2 trial |
| Carmot Therapeutics | CT-868 | treatment of overweight and obese patients with Type 2 diabetes | IND for a phase 2 trial granted by the FDA |
| City of Hope | mushroom powder tablets | prostate-specific antigen levels | recruiting begun in phase 2 trial |
| Tessa Therapeutics | autologous CD30 CAR-T in relapsed/refractory cHL | relapsed or refractory Hodgkins lymphoma | enrollment of 12-patient cohort complete in phase 2 trial |
| Galmed Pharmaceuticals | Aramchol | nonalcoholic steatohepatitis and fibrosis | IND for phase 3 trial granted by China’s National Medical Products Administration |
| Catalyst Biosciences | MarzAA | hemophilia A or B with inhibitors | first patient dosed in phase 3 trial |
| Isofol Medical | Arfolitixorin | first-line metastatic colorectal cancer | recruiting complete in global phase 3 trial |
| ObSeva | Yslty | moderate-to-severe endometriosis-associated pain | enrollment complete in phase 3 trial |
| Praxis Precision Medicines | PRAX-562 | SCN2A development and epileptic encephalopathy | Orphan Drug designation granted by the FDA |
| Cerapedics | P-15L | bone graft in cases of degenerative disc disease | Breakthrough Device designation awarded by the FDA |
| AstraZeneca | Farxiga (dapagliflozin) oral tablets | kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression | approved by the FDA |
| Chiesi Global Rare Diseases | Ferriprox (deferiprone) | transfusional iron overload caused by sickle cell disease or other anemias in adults and children ages three years and older | approved by the FDA |
| Merck | Keytruda in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy | locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma | approved by the FDA |
Upcoming Events
-
13Jul
-
22Jul
-
28Sep
-
18Oct
